Ultragenyx Pharmaceutical Inc

詳細情報 Ultragenyx Pharmaceutical Inc 企業名

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.

企業情報

企業コードRARE

会社名Ultragenyx Pharmaceutical Inc

上場日Jan 31, 2014

設立日2011

最高経営責任者「CEO」Dr. Emil D. Kakkis, M.D., Ph.D.

従業員数1294

証券種類Ordinary Share

決算期末Jan 31

本社所在地60 Leveroni Ct

都市NOVATO

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号94949

電話番号14154838800

ウェブサイトhttps://www.ultragenyx.com/

企業コードRARE

上場日Jan 31, 2014

設立日2011

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Emil D. Kakkis, M.D., Ph.D.

President, Chief Executive Officer, Director

2.69M

-1.17%

Mr. Dennis Karl Huang

Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations

107.20K

+41.78%

Mr. Erik Harris

Executive Vice President, Chief Commercial Officer

41.99K

+83.47%

Mr. Daniel G. Welch

Independent Chairman of the Board

27.34K

+26.57%

Mr. Michael A. Narachi

Independent Director

27.34K

+26.57%

Dr. Shehnaaz Suliman, M.D.

Independent Director

20.59K

+38.64%

Dr. Amrit Ray, M.D.

Independent Director

18.02K

+46.74%

Mr. Howard Horn

Chief Financial Officer, Executive Vice President, Corporate Strategy

15.69K

-83.00%

Mr. John R. Pinion, II

Chief Quality Officer, Executive Vice President - Translational Sciences

--

Dr. Deborah L. Dunsire, M.D.

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Emil D. Kakkis, M.D., Ph.D.

President, Chief Executive Officer, Director

2.69M

-1.17%

Mr. Dennis Karl Huang

Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations

107.20K

+41.78%

Mr. Erik Harris

Executive Vice President, Chief Commercial Officer

41.99K

+83.47%

Mr. Daniel G. Welch

Independent Chairman of the Board

27.34K

+26.57%

Mr. Michael A. Narachi

Independent Director

27.34K

+26.57%

Dr. Shehnaaz Suliman, M.D.

Independent Director

20.59K

+38.64%

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

事業別USD

会社名

収益

比率

Crysvita

55.08M

39.54%

Crysvita royalty revenue

47.78M

34.31%

Dojolvi

17.01M

12.21%

Evkeeza

11.03M

7.92%

Mepsevii

8.39M

6.02%

地域別USD

会社名

収益

比率

North America

57.79M

41.49%

Latin America

54.89M

39.40%

Europe

23.33M

16.75%

Japan

3.29M

2.36%

事業別

地域別

事業別USD

会社名

収益

比率

Crysvita

55.08M

39.54%

Crysvita royalty revenue

47.78M

34.31%

Dojolvi

17.01M

12.21%

Evkeeza

11.03M

7.92%

Mepsevii

8.39M

6.02%

株主

更新時刻: Sat, May 17

株主統計

種類

株主統計

比率

The Vanguard Group, Inc.

10.55%

BlackRock Institutional Trust Company, N.A.

5.20%

Sands Capital Management, LLC

4.40%

T. Rowe Price Associates, Inc.

3.32%

Kakkis (Emil D)

2.85%

Other

73.68%

株主統計

比率

The Vanguard Group, Inc.

10.55%

BlackRock Institutional Trust Company, N.A.

5.20%

Sands Capital Management, LLC

4.40%

T. Rowe Price Associates, Inc.

3.32%

Kakkis (Emil D)

2.85%

Other

73.68%

種類

株主統計

比率

Investment Advisor/Hedge Fund

44.96%

Investment Advisor

27.79%

Hedge Fund

21.16%

Individual Investor

3.56%

Research Firm

1.72%

Sovereign Wealth Fund

1.02%

Private Equity

0.70%

Pension Fund

0.65%

Bank and Trust

0.28%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

627

96.81M

102.40%

-2.03M

2025Q1

652

96.83M

102.45%

-3.19M

2024Q4

645

94.29M

102.32%

-4.54M

2024Q3

633

93.51M

101.49%

-6.93M

2024Q2

618

95.17M

101.90%

+3.05M

2024Q1

605

86.17M

101.67%

-4.74M

2023Q4

588

86.44M

105.27%

+5.64M

2023Q3

574

75.90M

106.07%

-3.60M

2023Q2

591

75.05M

105.07%

-3.13M

2023Q1

609

74.12M

105.56%

-2.85M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

The Vanguard Group, Inc.

9.98M

10.55%

-38.64K

-0.39%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

4.91M

5.2%

-49.62K

-1.00%

Mar 31, 2025

Sands Capital Management, LLC

4.16M

4.4%

-134.44K

-3.13%

Mar 31, 2025

T. Rowe Price Associates, Inc.

3.14M

3.32%

+698.80K

+28.65%

Mar 31, 2025

Kakkis (Emil D)

2.69M

2.85%

-31.78K

-1.17%

Mar 07, 2025

State Street Global Advisors (US)

2.62M

2.77%

-104.13K

-3.82%

Mar 31, 2025

Wellington Management Company, LLP

2.45M

2.59%

-8.04K

-0.33%

Mar 31, 2025

ClearBridge Investments, LLC

2.26M

2.39%

-62.50K

-2.69%

Mar 31, 2025

Adage Capital Management, L.P.

2.15M

2.27%

+965.92K

+81.64%

Mar 31, 2025

Federated Hermes Global Investment Management Corp.

2.05M

2.17%

+3.00K

+0.15%

Mar 31, 2025

詳細を見る

31.035USD

Ultragenyx Pharmaceutical Inc

31.035

概要

企業名

金融